Vanguard Amends Regeneron Stake: Holds 7.6% as of Dec 29, 2023

TL;DR

**Vanguard still owns 7.6% of Regeneron, showing continued institutional confidence.**

AI Summary

The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, disclosing its ownership in Regeneron Pharmaceuticals Inc. As of December 29, 2023, Vanguard reported beneficial ownership of 8,502,745 shares of Regeneron's Common Stock, representing 7.6% of the company's outstanding shares. This filing indicates Vanguard's continued significant, but passive, investment in Regeneron, which is important for investors as large institutional holdings can provide stability and signal confidence in the company's long-term prospects.

Why It Matters

This filing shows that a major institutional investor, Vanguard, maintains a substantial stake in Regeneron, which can influence stock stability and investor confidence.

Risk Assessment

Risk Level: low — This is a routine update from a passive institutional investor, indicating no immediate change in company control or strategy.

Analyst Insight

Investors should note Vanguard's continued significant, but passive, stake in Regeneron, which suggests long-term institutional confidence without indicating any immediate strategic changes or activist intent.

Key Numbers

• 8,502,745 — Shares Beneficially Owned (Represents the total number of Regeneron shares Vanguard holds, indicating a significant investment.)
• 7.6% — Percentage of Class (Shows Vanguard's substantial ownership stake in Regeneron, making them a key institutional holder.)
• December 29, 2023 — Date of Event (The snapshot date for the reported ownership, providing a clear reference point for the disclosed stake.)

Key Players & Entities

• The Vanguard Group (company) — the reporting person and institutional investor
• Regeneron Pharmaceuticals Inc (company) — the subject company whose securities are being reported
• 8,502,745 (dollar_amount) — number of shares beneficially owned by Vanguard
• 7.6% (dollar_amount) — percentage of Regeneron's class of securities beneficially owned by Vanguard
• December 29, 2023 (date) — the date of the event requiring the filing
• February 13, 2024 (date) — the filing date of the SC 13G/A

Forward-Looking Statements

• Vanguard will maintain a significant, passive stake in Regeneron Pharmaceuticals Inc. (The Vanguard Group) — high confidence, target: Next 12 months

FAQ

Filing Documents

• tv01800-regeneronpharmaceuti.htm (SC 13G/A) — 11KB
• 0001104659-24-021814.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: Regeneron Pharmaceuticals Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: 777 Old Saw Mill River Road Tarrytown, NY 10591-6707

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 75886F107

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR